To further investigate the role of PI3K/Akt/mTOR pathway inhibition in BL, additional experiments were performed with the PI3K-delta isoform specific inhibitor idelalisib, which is already FDA approved for relapsed/refractory CLL/SLL and FL. Here, MTOR is linked to B-cell chronic lymphocytic leukemia.